

Didier A Mandelbrot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8773205/publications.pdf>

Version: 2024-02-01

208
papers

4,685
citations

145106

33
h-index

150775

59
g-index

208
all docs

208
docs citations

208
times ranked

5497
citing authors

#	ARTICLE	IF	CITATIONS
1	Motivations and outcomes of compatible living donor-recipient pairs in paired exchange. American Journal of Transplantation, 2022, 22, 266-273.	2.6	13
2	Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity. Transplant Infectious Disease, 2022, 24, e13766.	0.7	12
3	Risk factors and outcomes of BK viremia among deceased donor kidney transplant recipients based on donor characteristics. Transplant Infectious Disease, 2022, 24, e13768.	0.7	3
4	Factors affecting sensitization following kidney allograft failure. Clinical Transplantation, 2022, 36, e14558.	0.8	3
5	Understanding and Overcoming Financial Risks for Living Organ Donors. American Journal of Kidney Diseases, 2022, 79, 159-161.	2.1	5
6	Utility of Protocol Pancreas Biopsies for De Novo Donor-specific Antibodies. Transplantation Direct, 2022, 8, e1287.	0.8	2
7	How Should Acute T-cell Mediated Rejection of Kidney Transplants Be Treated: Importance of Follow-up Biopsy. Transplantation Direct, 2022, 8, e1305.	0.8	5
8	Transplant Recipient Experience With Belatacept Therapy. Transplantation Proceedings, 2022, 54, 1604-1608.	0.3	1
9	The Presence of Donor-specific Antibodies Around the Time of Pancreas Graft Biopsy With Rejection Is Associated With an Increased Risk of Graft Failure. Transplantation, 2022, 106, e289-e296.	0.5	3
10	Cytomegalovirus antiviral stewardship in solid organ transplant recipients: A new gold standard. Transplant Infectious Disease, 2022, 24, .	0.7	16
11	Kidney delayed graft function after combined kidney-solid organ transplantation: A review. Transplantation Reviews, 2022, 36, 100707.	1.2	4
12	In kidney recipients from the same deceased donor, discordance in delayed graft function is associated with the worst outcomes. Clinical Transplantation, 2022, 36, .	0.8	5
13	Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 475-483.	2.6	45
14	Kidney transplantation for primary glomerulonephritis: Recurrence risk and graft outcomes with related versus unrelated donors. Transplantation Reviews, 2021, 35, 100584.	1.2	0
15	Incidence, risk factors, and outcomes of post-transplant erythrocytosis after kidney transplantation. Clinical Transplantation, 2021, 35, e14166.	0.8	7
16	Single center results of simultaneous pancreas-kidney transplantation in patients with type 2 diabetes. American Journal of Transplantation, 2021, 21, 2810-2823.	2.6	17
17	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. American Journal of Transplantation, 2021, 21, 460-474.	2.6	67
18	Risk factors for progression from low level BK dnaemia to unfavorable outcomes after BK management via immunosuppressive reduction. Transplant Infectious Disease, 2021, 23, e13561.	0.7	5

#	ARTICLE	IF	CITATIONS
19	Impact and outcomes of primary cytomegalovirus disease in seronegative abdominal solid organ transplant recipients of cytomegalovirus unexposed donors (Dâ€™Râ€™). Transplant Infectious Disease, 2021, 23, e13564.	0.7	3
20	Living Related Donor Kidney Transplantation in Atypical HUS: When Should It Be Considered?. Kidney360, 2021, 2, 524-527.	0.9	1
21	Risk factors and outcomes for delayed kidney graft function in simultaneous heart and kidney transplant recipients: A UNOS/OPTN database analysis. American Journal of Transplantation, 2021, 21, 3005-3013.	2.6	5
22	Wages, Travel, and Lodging Reimbursement by the National Kidney Registry: An Important Step Toward Financial Neutrality for Living Kidney Donors in the United States. Transplantation, 2021, 105, 2606-2611.	0.5	12
23	Graft Function Variability and Slope and Kidney Transplantation Outcomes. Kidney International Reports, 2021, 6, 1642-1652.	0.4	2
24	Cytomegalovirus antiviral stewardship in the COVIDâ€™19 Era: Increasing complexity of prophylaxis and treatment and potential mitigation strategies. Transplant Infectious Disease, 2021, 23, e13586.	0.7	9
25	Conversion from cytomegalovirus universal prophylaxis with valganciclovir to the preemptive monitoring approach to manage leukopenia after kidney or pancreas transplantation. Transplant Infectious Disease, 2021, 23, e13617.	0.7	5
26	Sodium zirconium cyclosilicate use in kidney transplant recipients. Nephrology Dialysis Transplantation, 2021, 36, 2151-2153.	0.4	2
27	Continuation of Peritoneal Dialysis in Adult Kidney Transplant Recipients With Delayed Graft Function. Kidney International Reports, 2021, 6, 1634-1641.	0.4	6
28	Successful management of Tâ€™cell mediated rejection in a recent kidney transplant recipient with COVIDâ€™19 associated severe acute respiratory syndrome. Transplant Infectious Disease, 2021, 23, e13598.	0.7	7
29	Bimonthly viral monitoring for lateâ€™onset cytomegalovirus infectionâ€™Balancing efficacy with patient palatability; A reply to Melgarejo et al. Clinical Transplantation, 2021, 35, e14348.	0.8	2
30	Geographic Distribution of Cytomegalovirus Serology in Kidney and Pancreas Transplant Recipients in the United States. Transplantation Direct, 2021, 7, e704.	0.8	6
31	Modest Improvements in Refractory Antibody-Mediated Rejection After Prolonged Treatment. Kidney International Reports, 2021, 6, 1397-1401.	0.4	1
32	Outcomes of Delayed Graft Function in Kidney Transplant Recipients Stratified by Histologic Biopsy Findings. Transplantation Proceedings, 2021, 53, 1462-1469.	0.3	10
33	Frailty in Pancreas Transplantation. Transplantation, 2021, 105, 1685-1694.	0.5	3
34	Postâ€™kidney transplant serum magnesium exhibits a Uâ€™shaped association with subsequent mortality: an observational cohort study. Transplant International, 2021, 34, 1853-1861.	0.8	4
35	Discrepant subtyping of blood type A2 living kidney donors: Missed opportunities in kidney transplantation. Clinical Transplantation, 2021, 35, e14422.	0.8	3
36	Transplant kidney biopsy for proteinuria with stable creatinine: Findings and outcomes. Clinical Transplantation, 2021, 35, e14436.	0.8	6

#	ARTICLE	IF	CITATIONS
37	The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13693.	0.7	13
38	The Evaluation of Kidney Function in Living Kidney Donor Candidates. <i>Kidney360</i> , 2021, 2, 1523-1530.	0.9	12
39	A pilot study of an intensified ganciclovir dosing strategy for treatment of cytomegalovirus disease in kidney and/or pancreas transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14427.	0.8	3
40	Pretransplant bariatric surgery is not associated with an increased risk of infection after kidney transplant. <i>Transplant International</i> , 2021, 34, 1989-1991.	0.8	2
41	Impact of low-level pretransplant donor-specific antibodies on outcomes after kidney transplantation. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1508-1519.	1.3	4
42	Cytomegalovirus nephritis in kidney transplant recipients: Epidemiology and outcomes of an uncommon diagnosis. <i>Transplant Infectious Disease</i> , 2021, 23, e13702.	0.7	5
43	Transplant Options for Patients With Diabetes and Advanced Kidney Disease: A Review. <i>American Journal of Kidney Diseases</i> , 2021, 78, 418-428.	2.1	17
44	Significance of Asymptomatic Pyelonephritis Found on Kidney Transplant Biopsy. <i>Transplantation Direct</i> , 2021, 7, e764.	0.8	1
45	The clinical value of donor-derived cell-free DNA measurements in kidney transplantation. <i>Transplantation Reviews</i> , 2021, 35, 100649.	1.2	9
46	Factors Associated With Residual Kidney Function and Proteinuria After Living Kidney Donation in the United States. <i>Transplantation</i> , 2021, 105, 372-381.	0.5	5
47	The Utility of Donor-specific Antibody Monitoring and the Role of Kidney Biopsy in Simultaneous Liver and Kidney Recipients With De Novo Donor-specific Antibodies. <i>Transplantation</i> , 2021, 105, 1548-1555.	0.5	8
48	Association of Human Leukocyte Antigen Mismatches Between Donor-recipient And Donor-donor in Pancreas after Kidney Transplant Recipients. <i>Transplant International</i> , 2021, , .	0.8	3
49	Long-Term Outcomes and Prognostic Factors in Kidney Transplant Recipients with Polycystic Kidney Disease. <i>Kidney360</i> , 2021, 2, 312-324.	0.9	6
50	Treatment of Chronic Active Antibody-mediated Rejection With Pulse Steroids, IVIG, With or Without Rituximab is Associated With Increased Risk of Pneumonia. <i>Transplantation Direct</i> , 2021, 7, e644.	0.8	3
51	P.131: Persistent Low Blood Pressure After Simultaneous Pancreas and Kidney Transplant Is not Associated With an Increased Risk of Allograft Loss. <i>Transplantation</i> , 2021, 105, S51-S51.	0.5	0
52	406.4: Induction in Pancreas Transplantation: T-cell Depletion vs. IL-2 Receptor Blockade. <i>Transplantation</i> , 2021, 105, S32-S32.	0.5	0
53	New Approaches to Cardiovascular Disease and its Management in Kidney Transplant Recipients. <i>Transplantation</i> , 2021, Publish Ahead of Print, .	0.5	3
54	Kidney transplant outcomes among recipients with posttransplant hip or knee joint replacement surgery. <i>Clinical Transplantation</i> , 2021, , e14564.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Living donor program crisis management plans: Current landscape and talking point recommendations. <i>American Journal of Transplantation</i> , 2020, 20, 546-552.	2.6	9
56	Patterns and predictors of fatigue following living donor nephrectomy: Findings from the KDOC Study. <i>American Journal of Transplantation</i> , 2020, 20, 181-189.	2.6	13
57	Performance of Creatinine Clearance and Estimated GFR in Assessing Kidney Function in Living Donor Candidates. <i>Transplantation</i> , 2020, 104, 575-582.	0.5	9
58	More Than 25 Years of Pancreas Graft Survival After Simultaneous Pancreas and Kidney Transplantation: Experience From the World's Largest Series of Long-term Survivors. <i>Transplantation</i> , 2020, 104, 1287-1293.	0.5	12
59	Induction and Donor Specific Antibodies in Low Immunologic Risk Kidney Transplant Recipients. <i>Kidney360</i> , 2020, 1, 1407-1418.	0.9	4
60	Characteristics and Graft Survival of Kidney Transplant Recipients with Renal Cell Carcinoma. <i>American Journal of Nephrology</i> , 2020, 51, 777-785.	1.4	3
61	A Single-Center Assessment of Delayed Graft Function in Recipients of Simultaneous Liver and Kidney Transplant. <i>Progress in Transplantation</i> , 2020, 30, 342-348.	0.4	3
62	Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Injury in Kidney Transplant Recipients During the Time of the Coronavirus Disease 2019 Pandemic. <i>Transplantation Proceedings</i> , 2020, 52, 2592-2595.	0.3	6
63	The care of kidney transplant recipients during a global pandemic: Challenges and strategies for success. <i>Transplantation Reviews</i> , 2020, 34, 100567.	1.2	9
64	Alloimmunity in pancreas transplantation. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 322-328.	0.8	9
65	Serum Albumin Level Before Kidney Transplant Predicts Post-transplant BK and Possibly Cytomegalovirus Infection. <i>Kidney International Reports</i> , 2020, 5, 2228-2237.	0.4	10
66	Early Report on Published Outcomes in Kidney Transplant Recipients Compared to Nontransplant Patients Infected With Coronavirus Disease 2019. <i>Transplantation Proceedings</i> , 2020, 52, 2659-2662.	0.3	21
67	Donor-specific antibodies in kidney transplantation: the University of Wisconsin experience. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 543-548.	0.8	2
68	Editorial: The cutting edge of donor-specific antibodies in transplantation. <i>Current Opinion in Organ Transplantation</i> , 2020, 25, 527-528.	0.8	0
69	Care of international living kidney donor candidates in the United States: A survey of contemporary experience, practice, and challenges. <i>Clinical Transplantation</i> , 2020, 34, e14064.	0.8	10
70	Obesity: An Independent Predictor of Morbidity and Graft Loss after Kidney Transplantation. <i>American Journal of Nephrology</i> , 2020, 51, 615-623.	1.4	14
71	Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era. <i>Kidney International Reports</i> , 2020, 5, 1894-1905.	0.4	54
72	The kidney evaluation of living kidney donor candidates: US practices in 2017. <i>American Journal of Transplantation</i> , 2020, 20, 3379-3389.	2.6	29

#	ARTICLE	IF	CITATIONS
73	Metabolic, cardiovascular, and substance use evaluation of living kidney donor candidates: US practices in 2017. <i>American Journal of Transplantation</i> , 2020, 20, 3390-3400.	2.6	21
74	Epidemiology, management, and graft outcomes after West Nile virus encephalitis in kidney transplant recipients. <i>Transplant Infectious Disease</i> , 2020, 22, e13317.	0.7	9
75	Third-party vessel allografts in kidney and pancreas transplantation: Utilization, de novo DSAs, and outcomes. <i>American Journal of Transplantation</i> , 2020, 20, 3443-3450.	2.6	3
76	Prediction of cytomegalovirus infection: A single-center experience utilizing a newly available cell-mediated immunity assay by flow cytometry, a risk factor screening tool, and serologically demonstrated immunity. <i>Transplant Infectious Disease</i> , 2020, 22, e13311.	0.7	10
77	The development and implementation of stewardship initiatives to optimize the prevention and treatment of cytomegalovirus infection in solid-organ transplant recipients. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1068-1074.	1.0	21
78	Outcomes of simultaneous pancreas and kidney transplants based on preemptive transplant compared to those who were on dialysis before transplant – a retrospective study. <i>Transplant International</i> , 2020, 33, 1106-1115.	0.8	8
79	Prevalence of primary aldosteronism in hypertensive kidney transplant recipients: A cross-sectional study. <i>Clinical Transplantation</i> , 2020, 34, e13999.	0.8	4
80	Pain expectancy, prevalence, severity, and patterns following donor nephrectomy: Findings from the KDOC Study. <i>American Journal of Transplantation</i> , 2020, 20, 2522-2529.	2.6	10
81	Mycophenolate Monotherapy in HLA-Matched Kidney Transplant Recipients: A Case Series of 20 Patients. <i>Transplantation Direct</i> , 2020, 6, e526.	0.8	0
82	Incidence and Outcomes of Significant Weight Changes After Pancreas Transplant Alone. <i>Transplantation Direct</i> , 2020, 6, e539.	0.8	3
83	Polyomavirus and cytomegalovirus infections are risk factors for grafts loss in simultaneous pancreas and kidney transplant. <i>Transplant Infectious Disease</i> , 2020, 22, e13272.	0.7	6
84	Unusually high rates of acute rejection during the COVID-19 pandemic: cause for concern?. <i>Kidney International</i> , 2020, 98, 513-514.	2.6	20
85	One more time, emphasizing the advantage of simultaneous pancreas and kidney transplantation for patients with type 1 diabetes and end-stage renal disease. <i>Transplant International</i> , 2020, 33, 1384-1386.	0.8	4
86	Evaluation and care of international living kidney donor candidates: Strategies for addressing common considerations and challenges. <i>Clinical Transplantation</i> , 2020, 34, e13792.	0.8	8
87	Management of BK viremia is associated with a lower risk of subsequent cytomegalovirus infection in kidney transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e13798.	0.8	10
88	Delayed kidney graft function in simultaneous pancreas-kidney transplant recipients is associated with early pancreas allograft failure. <i>American Journal of Transplantation</i> , 2020, 20, 2822-2831.	2.6	8
89	KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. <i>American Journal of Kidney Diseases</i> , 2020, 75, 299-316.	2.1	38
90	Short-Term Immunopathological Changes Associated with Pulse Steroids/IVIG/Rituximab Therapy in Late Kidney Allograft Antibody Mediated Rejection. <i>Kidney360</i> , 2020, 1, 389-398.	0.9	5

#	ARTICLE	IF	CITATIONS
91	Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction. <i>Clinical Nephrology</i> , 2020, 93, 77-84.	0.4	6
92	Non-obstructive coronary angiogram findings prior to kidney transplantation do not predict post-transplant cardiac events. <i>Clinical Nephrology</i> , 2020, 94, 273-280.	0.4	4
93	Role of novel biomarkers in kidney transplantation. <i>World Journal of Transplantation</i> , 2020, 10, 230-255.	0.6	26
94	Pre-transplant AT1R antibodies and long-term outcomes in kidney transplant recipients with a functioning graft for more than 5 years. <i>Clinical Nephrology</i> , 2020, 94, 245-251.	0.4	2
95	Lipid lowering in dialysis patients with cardiovascular disease who are awaiting kidney transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13452.	0.8	1
96	Outcomes after simultaneous kidney-pancreas versus pancreas after kidney transplantation in the current era. <i>Clinical Transplantation</i> , 2019, 33, e13732.	0.8	17
97	Association of diagnosed obstructive sleep apnea with kidney transplant outcomes. <i>Clinical Transplantation</i> , 2019, 33, .	0.8	6
98	The association of acute rejection vs recurrent glomerular disease with graft outcomes after kidney transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13738.	0.8	3
99	<i>Nocardia</i> infection in kidney transplant recipients: A single-center experience. <i>Transplant Infectious Disease</i> , 2019, 21, e13192.	0.7	8
100	The risk of cytomegalovirus infection after treatment of acute rejection in renal transplant recipients. <i>Clinical Transplantation</i> , 2019, 33, e13636.	0.8	13
101	Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure. <i>Kidney International Reports</i> , 2019, 4, 1057-1065.	0.4	29
102	Clinical Significance of Microvascular Inflammation in the Absence of Anti-HLA DSA in Kidney Transplantation. <i>Transplantation</i> , 2019, 103, 1468-1476.	0.5	29
103	Risk of opportunistic infection in kidney transplant recipients with cytomegalovirus infection and associated outcomes. <i>Transplant Infectious Disease</i> , 2019, 21, e13080.	0.7	17
104	Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes. <i>Transplantation</i> , 2019, 103, 1722-1729.	0.5	76
105	The Association of 25-Hydroxyvitamin D Levels with Late Cytomegalovirus Infection in Kidney Transplant Recipients: the Wisconsin Allograft Recipient Database. <i>Transplantation</i> , 2019, 103, 1683-1688.	0.5	7
106	Harald C. Ott: Clinician-scientist, Cardiothoracic Surgeon, Massachusetts General Hospital, Harvard Medical School. <i>Transplantation</i> , 2019, 103, 862-863.	0.5	24
107	Pancreas Retransplant After Pancreas Graft Failure in Simultaneous Pancreas-kidney Transplants Is Associated With Better Kidney Graft Survival. <i>Transplantation Direct</i> , 2019, 5, e473.	0.8	7
108	Hospitalization Trends for Acute Kidney Injury in Kidney Transplant Recipients in the United States, 2004-2014. <i>Transplantation</i> , 2019, 103, 2405-2412.	0.5	5

#	ARTICLE	IF	CITATIONS
109	How Should Pancreas Transplant Rejection Be Treated?. <i>Transplantation</i> , 2019, 103, 1928-1934.	0.5	17
110	Rates of Living Kidney Donor Follow-up: Findings From the KDOC Study. <i>Transplantation</i> , 2019, 103, e209-e210.	0.5	2
111	Management of Tumor Necrosis Factor $\hat{\pm}$ Inhibitor Therapy After Renal Transplantation: A Comparative Analysis and Associated Outcomes. <i>Annals of Pharmacotherapy</i> , 2019, 53, 268-275.	0.9	10
112	Sleep disorders: Serious threats among kidney transplant recipients. <i>Transplantation Reviews</i> , 2019, 33, 9-16.	1.2	14
113	Metabolic Acidosis 1 Year Following Kidney Transplantation and Subsequent Cardiovascular Events and Mortality: An Observational Cohort Study. <i>American Journal of Kidney Diseases</i> , 2019, 73, 476-485.	2.1	26
114	Histopathological characteristics and causes of kidney graft failure in the current era of immunosuppression. <i>World Journal of Transplantation</i> , 2019, 9, 123-133.	0.6	27
115	Risk factors for graft loss in kidney transplant recipients with g3 glomerulitis: A single-center experience. <i>Clinical Nephrology</i> , 2019, 91, 95-100.	0.4	2
116	Demonstration of Resistant or Wild-Type Virus in Recurrent Viremia After Ganciclovir-Resistant Cytomegaloviral Infection. <i>Annals of Pharmacotherapy</i> , 2018, 52, 650-654.	0.9	1
117	The Living Donor Lost Wages Trial: Study Rationale and Protocol. <i>Current Transplantation Reports</i> , 2018, 5, 45-54.	0.9	7
118	Which is more nephrotoxic for kidney transplants: <sc>BK</sc> nephropathy or rejection?. <i>Clinical Transplantation</i> , 2018, 32, e13216.	0.8	22
119	Concurrent biopsies of both grafts in recipients of simultaneous pancreas and kidney demonstrate high rates of discordance for rejection as well as discordance in type of rejection - a retrospective study. <i>Transplant International</i> , 2018, 31, 32-37.	0.8	27
120	Seasonality of mortality and graft failure among kidney transplant recipients in the US - a retrospective study. <i>Transplant International</i> , 2018, 31, 293-301.	0.8	8
121	Addressing Disparities in Living Donor Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1909-1911.	2.2	27
122	Pneumocystis jiroveci pneumonia in kidney and simultaneous pancreas kidney transplant recipients in the present era of routine post-transplant prophylaxis: risk factors and outcomes. <i>BMC Nephrology</i> , 2018, 19, 332.	0.8	15
123	Impact of High-Dose Acyclovir Cytomegalovirus Prophylaxis Failure in Abdominal Solid Organ Transplant Recipients. <i>Pharmacotherapy</i> , 2018, 38, 694-700.	1.2	9
124	The feared five fungal infections in kidney transplant recipients: A single-center 20-year experience. <i>Clinical Transplantation</i> , 2018, 32, e13289.	0.8	15
125	<sc>BK</sc> viremia is not associated with adverse outcomes in the absence of <sc>BK</sc> nephropathy. <i>Clinical Transplantation</i> , 2018, 32, e13283.	0.8	10
126	Hypertension guidelines: How do they apply to kidney transplant recipients. <i>Transplantation Reviews</i> , 2018, 32, 225-233.	1.2	19

#	ARTICLE	IF	CITATIONS
127	Characteristics and Outcomes of Kidney Transplant Recipients with a Functioning Graft for More than 25 Years. <i>Kidney Diseases (Basel, Switzerland)</i> , 2018, 4, 255-261.	1.2	14
128	The Living Donor Lost Wages Trial: Study Rationale and Protocol. <i>Current Transplantation Reports</i> , 2018, 5, 45-54.	0.9	2
129	Barriers to the use of a federal travel grant by living kidney donors. <i>Clinical Transplantation</i> , 2017, 31, e12876.	0.8	8
130	Life with One Kidney: Primary Care and the Living Kidney Donor. <i>American Journal of Medicine</i> , 2017, 130, 763-765.	0.6	1
131	Outcomes in the highest panel reactive antibody recipients of deceased donor kidneys under the new kidney allocation system. <i>Clinical Transplantation</i> , 2017, 31, e12895.	0.8	10
132	Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature. <i>Pharmacotherapy</i> , 2017, 37, 1258-1271.	1.2	27
133	Predictors and Moderators of Educational Interventions to Increase the Likelihood of Potential Living Donors for Black Patients Awaiting Kidney Transplantation. <i>Journal of Racial and Ethnic Health Disparities</i> , 2017, 4, 837-845.	1.8	14
134	Incidence and Indications for Late Allograft Pancreatectomy While on Continued Immunosuppression. <i>Transplantation</i> , 2017, 101, 2228-2234.	0.5	10
135	Utility of protocol kidney biopsies for de novo donor-specific antibodies. <i>American Journal of Transplantation</i> , 2017, 17, 3210-3218.	2.6	40
136	Practices in the evaluation of potential kidney transplant recipients who are elderly: A survey of U.S. transplant centers. <i>Clinical Transplantation</i> , 2017, 31, e13088.	0.8	19
137	Moving from Intuition to Data: Building the Evidence to Support and Increase Living Donor Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1383-1385.	2.2	14
138	Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation. <i>Transplantation Direct</i> , 2017, 3, e227.	0.8	34
139	Kidney Transplant Recipients With Primary Membranous Glomerulonephritis Have a Higher Risk of Acute Rejection Compared With Other Primary Glomerulonephritides. <i>Transplantation Direct</i> , 2017, 3, e223.	0.8	6
140	Pre-transplant immune factors may be associated with BK polyomavirus reactivation in kidney transplant recipients. <i>PLoS ONE</i> , 2017, 12, e0177339.	1.1	12
141	A single center kidney transplant experience among ten Caucasian females with end-stage renal disease due to scleroderma. <i>Clinical Nephrology</i> , 2017, 88, 40-44.	0.4	1
142	The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1746-1753.	0.4	63
143	In Kidney Transplant Recipients With a Positive Virtual Crossmatch, High PRA was Associated With Lower Incidence of Viral Infections. <i>Transplantation</i> , 2016, 100, 655-661.	0.5	12
144	Concern for Lost Income Following Donation Deters Some Patients From Talking to Potential Living Donors. <i>Progress in Transplantation</i> , 2016, 26, 292-298.	0.4	17

#	ARTICLE	IF	CITATIONS
145	Nature, timing, and severity of complications from ultrasound-guided percutaneous renal transplant biopsy. <i>Transplant International</i> , 2016, 29, 167-172.	0.8	68
146	Current outcomes of chronic active antibody mediated rejection – A large single center retrospective review using the updated BANFF 2013 criteria. <i>Human Immunology</i> , 2016, 77, 346-352.	1.2	70
147	To tell or not to tell: attitudes of transplant surgeons and transplant nephrologists regarding the disclosure of recipient information to living kidney donors. <i>Clinical Transplantation</i> , 2015, 29, 1203-1212.	0.8	4
148	Renal Function and Transplantation in Liver Disease. <i>Transplantation</i> , 2015, 99, 1756-1764.	0.5	31
149	Evaluation of high-risk living kidney donors. <i>Frontiers in Bioscience - Elite</i> , 2015, 7, 181-192.	0.9	1
150	Living Donor Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1687-1695.	2.2	101
151	Patient-Reported Outcomes Following Living Kidney Donation: A Single Center Experience. <i>Journal of Clinical Psychology in Medical Settings</i> , 2015, 22, 160-168.	0.8	26
152	Concerns of ABO incompatible and crossmatch–positive potential donors and recipients about participating in kidney exchanges. <i>Clinical Transplantation</i> , 2015, 29, 233-241.	0.8	7
153	Disclosing Health and Health Behavior Information between Living Donors and Their Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1609-1616.	2.2	9
154	Long-term evaluation of analytical methods used in sirolimus therapeutic drug monitoring. <i>Clinical Transplantation</i> , 2014, 28, 243-251.	0.8	14
155	Development and validation of a questionnaire to assess fear of kidney failure following living donation. <i>Transplant International</i> , 2014, 27, 570-575.	0.8	13
156	Making House Calls Increases Living Donor Inquiries and Evaluations for Blacks on the Kidney Transplant Waiting List. <i>Transplantation</i> , 2014, 98, 979-986.	0.5	101
157	Hospitalizations Following Living Donor Nephrectomy in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 355-365.	2.2	29
158	Kidney Donation and Risk of ESRD. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 92.	3.8	5
159	The Outcomes of Living Kidney Donation from Medically Complex Donors: Implications for the Donor and the Recipient. <i>Current Transplantation Reports</i> , 2014, 1, 1-9.	0.9	17
160	Efficacy of Levofloxacin in the Treatment of BK Viremia. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 583-589.	2.2	79
161	Readiness of Wait-Listed Black Patients to Pursue Live Donor Kidney Transplant. <i>Progress in Transplantation</i> , 2014, 24, 355-361.	0.4	21
162	Trajectories of Perceived Benefits in Living Kidney Donors. <i>Transplantation</i> , 2014, 97, 762-768.	0.5	19

#	ARTICLE	IF	CITATIONS
163	A Simultaneous Liver-Kidney Transplant Recipient With IgA Nephropathy Limited to Native Kidneys and BK Virus Nephropathy Limited to the Transplant Kidney. <i>American Journal of Kidney Diseases</i> , 2013, 62, 331-334.	2.1	3
164	Renal Transplantation in the Setting of Early Steroid Withdrawal: A Comparison of Rabbit Antithymocyte Globulin Induction Dosing in Two Eras. <i>American Journal of Nephrology</i> , 2013, 38, 397-404.	1.4	5
165	Comorbidity Burden and Perioperative Complications for Living Kidney Donors in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1773-1782.	2.2	88
166	Immunosuppression after renal allograft failure: a survey of <sc>US</sc> practices. <i>Clinical Transplantation</i> , 2013, 27, 895-900.	0.8	29
167	Willingness to Pursue Live-Donor Kidney Transplantation Among Waitlisted Patients Infected With Human Immunodeficiency Virus (HIV). <i>Transplantation</i> , 2013, 95, 787-790.	0.5	6
168	The Living Kidney Donor Evaluation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 366-371.	2.2	29
169	Evaluation of Native Kidney Recovery After Simultaneous Liver-Kidney Transplantation. <i>Transplantation</i> , 2012, 93, 530-535.	0.5	27
170	Living Donor Practices in the United States. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 212-219.	0.6	51
171	Liver transplant center risk tolerance. <i>Clinical Transplantation</i> , 2012, 26, E269-76.	0.8	4
172	Evaluation of relative renal function for patients who had undergone simultaneous liver"kidney transplants using Tc-99m-MAG3 scintigraphy with attenuation correction from anatomical images and SPECT/CT. <i>Nuclear Medicine Communications</i> , 2011, 32, 738-744.	0.5	15
173	A cross-sectional study of fatigue and sleep quality before and after kidney transplantation. <i>Clinical Transplantation</i> , 2011, 25, E13-E21.	0.8	50
174	2011 Recommendations for the Diagnosis and Management of Gout and Hyperuricemia. <i>Postgraduate Medicine</i> , 2011, 123, 3-36.	0.9	92
175	A psychological intervention to improve quality of life and reduce psychological distress in adults awaiting kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 709-715.	0.4	120
176	The Evolving Role of mTOR Inhibition in Transplantation Tolerance. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 408-415.	3.0	60
177	Renal Allograft Failure Predictors After PAK Transplantation: Results From the New England Collaborative Association of Pancreas Programs. <i>Transplantation</i> , 2010, 89, 1347-1353.	0.5	21
178	mTOR inhibition: the learning curve in kidney transplantation. <i>Transplant International</i> , 2010, 23, 447-460.	0.8	28
179	Spouse caregivers of kidney transplant patients: quality of life and psychosocial outcomes. <i>Progress in Transplantation</i> , 2010, 20, 335-343.	0.4	25
180	Anti"IL-2 Receptor Antibodies versus Anti-Thymocyte Globulin for Induction Therapy in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2009, 20, 1170-1171.	3.0	6

#	ARTICLE	IF	CITATIONS
181	Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients. <i>Clinical Transplantation</i> , 2009, 23, 887-896.	0.8	30
182	Outcomes With Conversion From Calcineurin Inhibitors to Sirolimus After Renal Transplantation in the Context of Steroid Withdrawal or Steroid Continuation. <i>Transplantation</i> , 2009, 88, 684-692.	0.5	10
183	Practices and Barriers in Long-Term Living Kidney Donor Follow-Up: A Survey of U.S. Transplant Centers. <i>Transplantation</i> , 2009, 88, 855-860.	0.5	65
184	Spotting the owl: surreptitious cytomegalovirus disease in a renal transplant recipient. <i>Clinical Transplantation</i> , 2008, 22, 391-395.	0.8	3
185	Web-based requests for living organ donors: who are the solicitors?. <i>Clinical Transplantation</i> , 2008, 22, 749-753.	0.8	15
186	Do We Know Enough to Mandate Donor Evaluation Testing?. <i>American Journal of Transplantation</i> , 2008, 8, 466-466.	2.6	1
187	Resolution of SLE-related soft-tissue calcification following haematopoietic stem cell transplantation. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2679-2684.	0.4	21
188	Measuring the Expectations of Kidney Donors: Initial Psychometric Properties of the Living Donation Expectancies Questionnaire. <i>Transplantation</i> , 2008, 85, 1230-1234.	0.5	20
189	Donor Postextubation Hypotension and Age Correlate With Outcome After Donation After Cardiac Death Transplantation. <i>Transplantation</i> , 2008, 85, 1588-1594.	0.5	73
190	Blockade of CTLA-4 on CD4+CD25+ Regulatory T Cells Abrogates Their Function In Vivo. <i>Journal of Immunology</i> , 2006, 177, 4376-4383.	0.4	368
191	CD70 Signaling Is Critical for CD28-Independent CD8+T Cell-Mediated Alloimmune Responses In Vivo. <i>Journal of Immunology</i> , 2005, 174, 1357-1364.	0.4	88
192	Mechanism of Action of Donor-Specific Transfusion in Inducing Tolerance: Role of Donor MHC Molecules, Donor Co-stimulatory Molecules, and Indirect Antigen Presentation. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 2423-2428.	3.0	40
193	Analysis of costimulation by 4-1BBL, CD40L, and B7 in graft rejection by gene expression profiles. <i>Journal of Molecular Medicine</i> , 2003, 81, 655-663.	1.7	6
194	Neutron-activation analysis: A novel method for the assay of iohexol. <i>Translational Research</i> , 2003, 141, 106-109.	2.4	7
195	Cutting Edge: Transplantation Tolerance through Enhanced CTLA-4 Expression. <i>Journal of Immunology</i> , 2003, 171, 5673-5677.	0.4	71
196	Role of novel T-cell costimulatory pathways in transplantation. <i>Current Opinion in Organ Transplantation</i> , 2003, 8, 25-33.	0.8	0
197	Cutting Edge: CTLA-4 (CD152) Differentially Regulates Mitogen-Activated Protein Kinases (Extracellular) Tj ETQq1 1 0.784314 rgBT /Ove Mice. <i>Journal of Immunology</i> , 2002, 169, 3475-3479.	0.4	68
198	Immunosuppression and BKV Nephropathy. <i>New England Journal of Medicine</i> , 2002, 347, 2079-2080.	13.9	30

#	ARTICLE	IF	CITATIONS
199	CTLA-4 regulates cell cycle progression during a primary immune response. <i>European Journal of Immunology</i> , 2002, 32, 366-373.	1.6	115
200	Rejection of Mouse Cardiac Allografts by Costimulation in <i>trans</i> . <i>Journal of Immunology</i> , 2001, 167, 1174-1178.	0.4	42
201	CD28-independent Costimulation of T Cells in Alloimmune Responses. <i>Journal of Immunology</i> , 2001, 167, 140-146.	0.4	109
202	B7-dependent T-cell costimulation in mice lacking CD28 and CTLA4. <i>Journal of Clinical Investigation</i> , 2001, 107, 881-887.	3.9	76
203	Molecular Basis for Leukocyte Integrin $\alpha 2 \beta 1$ Adhesion to Epithelial (E)-Cadherin. <i>Journal of Experimental Medicine</i> , 2000, 191, 1555-1567.	4.2	56
204	Association of B7-1 Co-Stimulation with the Development of Graft Arterial Disease. <i>American Journal of Pathology</i> , 2000, 157, 473-484.	1.9	40
205	B7-1 or B7-2 Is Required to Produce the Lymphoproliferative Phenotype in Mice Lacking Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA-4). <i>Journal of Experimental Medicine</i> , 1999, 189, 435-440.	4.2	137
206	CTLA-4 and T cell activation. <i>Current Opinion in Immunology</i> , 1999, 11, 294-300.	2.4	183
207	Distinct structural and functional epitopes of the $\alpha 2 \beta 1$ integrin. <i>European Journal of Immunology</i> , 1994, 24, 2832-2841.	1.6	72
208	Identification and Characterization of a Polypeptide from a Lobster Neurosecretory Gland that Induces Cyclic GMP Accumulation in Lobster Neuromuscular Preparations. <i>Journal of Neurochemistry</i> , 1987, 48, 954-966.	2.1	22